FDA tightens standards for COVID-19 antibody tests

The FDA cracked down on its policy for COVID-19 antibody tests after public health officials raised concerns over the quality of the tests, which were allowed on the market without FDA review, Politico reported. 

The agency said antibody test manufacturers must now apply for emergency use authorization within 10 business days after the products hit the market. If the tests don't meet the FDA's criteria, the manufacturer must suspend distribution, the agency said May 4.

The FDA was previously allowing any manufacturer to sell their antibody tests after validating the results themselves and simply notifying the agency of its plans to sell. 

Experts have raised concerns about the quality of the more than 100 tests the agency has allowed on the market without review. 

The agency will generally give emergency use authorization to tests that can detect 90 percent of people with COVID-19 antibodies and that produce false positives in less than 5 percent of cases, a senior FDA official told Politico

FDA Commissioner Stephen Hahn, MD, told Politico that the manufacturers of nearly half of the antibody tests already on the market under the old policy are working with the agency to get emergency use authorization. 

Read the full article here.

More articles on supply chain:
COVID-19 testing update: Where the US stands now
LabCorp offering free antibody tests for anyone with provider order
Kaiser building $14M COVID-19 testing facility

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers